Correlation of heart rate and blood pressure variability as well as hs-CRP with the burden of stable coronary artery disease

2020 ◽  
Vol 68 (5) ◽  
Author(s):  
Xiong Peng ◽  
Dingfeng Peng ◽  
Yongjun Hu ◽  
Hongsheng Gang ◽  
Yijun Yu ◽  
...  
Hypertension ◽  
2016 ◽  
Vol 67 (6) ◽  
pp. 1205-1210 ◽  
Author(s):  
Stefano F. Rimoldi ◽  
Franz H. Messerli ◽  
David Cerny ◽  
Steffen Gloekler ◽  
Tobias Traupe ◽  
...  

Author(s):  
Inga Balode ◽  
Sanda Jēgere ◽  
Iveta Bajāre ◽  
Iveta Mintāle ◽  
Inga Narbute ◽  
...  

Abstract The aim of the study was to evaluate control of heart rate (HR) and other risk factors (RF) over athree-year period in coronary artery disease (CAD) outpatients in Latvia. Patients (n = 120) were examined and questioned at baseline time and annually (four times in total). Increased resting HR (≥70 bpm) when measured by palpation was present in 35.8% of cases at baseline time, 35.6%, 29.8% and 35.1% of cases at Y1, Y2 and Y3, respectively; when measured by electrocardiography: in 33.6% (baseline), 36.8% (Y1), 26.7% (Y2), 33.7% (Y3) of cases. The proportion of patients with increased HR did not significantly change in Y1–Y3 vs baseline. Systolic blood pressure was lower in Y1 and Y3 vs baseline (P = 0.005 and P = 0.003, respectively). The proportion of patients with increased blood pressure (≥140/90 mmHg) was lower in Y1, Y2 and Y3 than at baseline (P = 0.018, P = 0.030 and P = 0.017, respectively). The proportion of patients with a decreased level of high density lipoprotein cholesterol (<1.2 mmol/l for women and <1.0 mmol/l fom men) was lower in Y1–Y3 compared to baseline (P < 0.001). A substantial (about one-third) and stable proportion of patients with increased HR≥70 bpm over the three-year period in the examined sample of treated CAD patients indicates that there is a need for better control of this RF.


1996 ◽  
Vol 85 (4) ◽  
pp. 706-712 ◽  
Author(s):  
Klaus-Dieter Stuhmeier ◽  
Bernd Mainzer ◽  
Jochen Cierpka ◽  
Wilhelm Sandmann ◽  
Jorg Tarnow

Background Most new perioperative myocardial ischemic episodes occur in the absence of hypertension or tachycardia. The ability of alpha 2-adrenoceptor agonists to inhibit central sympathetic outflow may benefit patients with coronary artery disease by increasing the myocardial oxygen supply and -demand ratio. Methods A randomized double-blind study design was used in 297 patients scheduled to have elective vascular surgical procedures to evaluate the effects of 2 micrograms/kg-1 oral clonidine (n = 145) or placebo (n = 152) on the incidence of perioperative myocardial ischemic episodes, myocardial infarction, and cardiac death. Continuous real-time S-T segment trend analysis (lead II and V5) was performed during anesthesia and surgery and correlated with arterial blood pressure and heart rate before and during ischemic events. Dose requirements for vasoactive and antiischemic drugs to control blood pressure and heart rate as well as episodes of myocardial ischemia (i.e., catecholamines, beta-adrenoceptor antagonists, nitrates, and systemic vasodilators) and fluid volume load were recorded. Results Administration of clonidine reduced the incidence of perioperative myocardial ischemic episodes from 39% (59 of 152) to 24% (35 of 145) (P &lt; 0.01). Hemodynamic patterns, percentage of ischemic time, and the number of ischemic episodes per patient did not differ. Nonfatal myocardial infarction developed after operation in four patients receiving placebo compared with none receiving clonidine (day 2 to 21; P = 0.07). The incidence of fatal cardiac events (1 vs. 2) was not different. Dose requirements for vasoactive and antiischemic drugs did not differ between the groups, but the amount of presurgical fluid volume was slightly greater in patients receiving clonidine (951 +/- 388 vs. 867 +/- 381 ml; P &lt; 0.03). Conclusion A small oral dose of clonidine, given prophylactically, can reduce the incidence of perioperative myocardial ischemic episodes without affecting hemodynamic stability in patients with suspected or documented coronary artery disease.


2009 ◽  
Vol 33 (1) ◽  
pp. 56-61 ◽  
Author(s):  
Tomasz Rechciński ◽  
Ewa Trzos ◽  
Karina Wierzbowska-Drabik ◽  
Maria Krzemińska-Pakuła ◽  
Małgorzata Kurpesa

Sign in / Sign up

Export Citation Format

Share Document